65 results about "Defensin" patented technology

Provided are compositions and methods employing Defensin peptides and proteins, including folding variants of antimicrobial Defensin peptides and proteins (DEF_PFV) that exhibit favorable antifungal properties and a desirable resistance or susceptibility to protease cleavage, which antimicrobial DEF_PFV can be applied ex vivo directly to a plant, human, or animal or can be administered in vivo to a plant, human, or animal.

The invention belongs to the fields of gene engineering, bioengineering and biological medicine, and relates to a nucleic acid molecule for coding human defensin, a method for preparing the human defensin and application. The nucleic acid sequence of the nucleic acid molecule comprises any one of the following sequences: (1) a sequence as shown in SEQ ID NO.2; (2) a nucleic acid sequence for coding human defensin, which is obtained by substituting, deleting or adding one or more than two nucleotides to the sequence as shown in SEQ ID NO.2; and (3) a nucleotide sequence which has at least 80% sequence homology with the nucleotide sequence in (1) or (2) and has the same or similar functions with the nucleotide sequence in (1) or (2). According to the method provided by the invention, the recombinant expression vector is constructed by using nucleic acid molecules for coding the human defensin, the human defensin hBD-3 can be recombined and expressed, the recombinant fusion protein is released to the supernatant of a culture solution, the protein purification is convenient, the obtained recombinant human defensin has a tissue regeneration function, and a new active molecule is provided for the development of a novel drug.

The invention provides an application of Ectoine or a derivative thereof as a human beta-defensin-2 expression promoter. According to the application, it is found for the first time that Ectoine or the derivative thereof has the effect of inducing cell expression of beta-defensin 2 (hBD-2), so that Ectoine or the derivative thereof is used for improving the defensive mechanism of skin antimicrobial.

The invention discloses an antibacterial peptide PPI45 / PPI47 as well as a preparation method and application of the antibacterial peptide PPI45 / PPI47. According to the invention, fungal defensin Plectasin is used as a template, and the self-assembled antibacterial peptide PPI45 / PPI47 is designed. The expression of the self-assembled antibacterial peptide PPI45 / PPI47 in pichia pastoris is realized by optimizing the gene sequence of the antibacterial peptide and constructing a specific expression vector, a perfect purification system is established, large-scale production can be realized, and the self-assembled antibacterial peptide PPI45 / PPI47 can be applied to the fields of antibacterial drug development, hydrogel wound treatment and the like, and has wide application value and market prospect.

The invention relates to a chicken beta-defensin-6 mutant based on AI aided design, a recombinant expression system and application, and relates to the technical field of gene engineering and protein engineering. The chicken beta defensin-6 mutant has the following amino acids at the following five sites: lysine at the 33rd site, lysine at the 35th site, asparagine at the 49th site, arginine at the 61st site and proline at the 65th site. The chicken beta-defensin-6 mutant has high stability, activity and solubility, compared with wild chicken beta-defensin-6, the chicken beta-defensin-6 mutant has higher antibacterial activity and expression level, an efficient and safe antibacterial substitute is provided for livestock and poultry breeding, and the chicken beta-defensin-6 mutant can be widely applied to the fields of livestock and poultry breeding, animal health care and biological preservation.

The invention provides an application of schizophyllan as a human beta-defensin-2 accelerant. According to the application, the effect of inducing human beta-defensin-2 (hBD-2) expression of the schizophyllan is found for the first time, and the schizophyllan can effectively stimulate an antimicrobial defense system on the surface of a human body to restore the stability of a natural internal environment, so that the schizophyllan is used for improving natural defense on the surface of the human body or improving microbiome balance on the surface of the human body; the active effects on prevention and / or reduction of skin infection, skin sensitivity, skin barrier damage and skin microecological disorder, prevention and improvement of pox muscles and the like are achieved, and the application field of the substance is widened.

The invention discloses a porcine beta-defensin-3 gene core promoter as well as a construction method and application thereof, and belongs to the technical field of gene engineering. The sequence of the core promoter is as shown in SEQ ID No.1, and the core promoter has remarkable promoter activity in porcine small intestine epithelial cells and can be regulated and controlled by nutrient substances sodium butyrate and glutamine. The invention also discloses a construction method for specifically amplifying the core promoter, which comprises the following steps: carrying out PCR (Polymerase Chain Reaction) amplification by taking porcine small intestine epithelial cell DNA (Deoxyribonucleic Acid) as a template, constructing a pMD-18T-pBD-3-P recombinant plasmid by taking upstream and downstream primers as shown in SEQ No.2-SEQ No.3, and amplifying by taking the recombinant plasmid as a template to obtain a core promoter fragment. The core promoter disclosed by the invention provides an excellent experimental system for researching a transcription regulation mechanism of the porcine beta-defensin-3 gene, the nutritional response characteristic of the core promoter provides a new platform for researching nutrition-immune interaction, and the core promoter has a wide application prospect in the field of healthy breeding of livestock and poultry.

The present invention discloses a method for using a biotherapy for novel coronavirus (SARS-CoV-2) infection, wherein the protein is DEFA1 (human defensin α1, or human neutrophil peptide, HNP-1). The reagents include but are not limited to: 1) DEFA1 recombinant protein; 2) a vector containing a DEFA1 encoding gene; 3) a reagent for detecting RNA expression of DEFA1. The experimental research results of the present invention provide a new biotherapy method for novel coronavirus infection, and provide a new drug target for treating respiratory tract lesions caused by novel coronavirus infection.

The application provides a composite antibacterial peptide preparation, a preparation method and application. The composite antibacterial peptide preparation comprises a first defensin, a second defensin, a first cecropin and a second cecropin. The amino acid sequence of the first defensin is shown in SEQ ID NO:1, the amino acid sequence of the second defensin is shown in SEQ ID NO:2, the amino acid sequence of the first cecropin is shown in SEQ ID NO:3, and the amino acid sequence of the second cecropin is shown in SEQ ID NO:4. Compared with a single antibacterial peptide, the composite antibacterial peptide preparation has good stability, and shows good inhibitory effect on various gram-positive bacteria, gram-negative bacteria and fungi.

The invention relates to the field of cell culture and discloses a culture medium for thick-shelled mussel mantle cells and an application thereof. The culture medium comprises a basal culture medium and additives, wherein the additives comprise thick-shelled mussel serum, proanthocyanidins, bovine insulin, growth factors, antibiotics, defensins, mussel mucin and a buffer. The culture medium can be used for in vitro culture of thick-shelled mussel mantle cells and can better maintain the survival and growth of in vitro cultured thick-shelled mussel mantle cells. Defensins in a specific proportion are added to the culture medium, and the best growth and reproduction state can be achieved when the thick-shelled mussel mantle cells are cultured using the culture medium in the specific proportion. The application also provides an application method of the culture medium, which is simple to operate and can produce cultured thick-shelled mussel mantle cells with high cell density, good morphology and high wall adhesion.

Antiviral peptides and formulations thereof are described for use in treating or preventing one or more symptoms of coronavirus infections. Peptides derived from human beta defensin 2 have been shown to have antiviral properties against different variants of coronavirus including cross-linking viral particles, blocking cell-to-cell fusion, and / or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via intranasal route to prevent or alleviate one or more symptoms of coronavirus infections such as reducing the syncytial formation and lung damage.

This invention discloses an oral vaccine against carp spring viremia virus, its preparation method, and its application. The oral vaccine is constructed by linking a carp spring viremia virus antigen protein and a Yellow River carp defensin protein via a flexible linker to form a fusion protein, which is then expressed in *E. coli* and enriched using a biological vector. The gene sequence encoding this fusion protein includes a truncated fragment of the carp spring viremia virus antigen protein gene (64-1389 bp), a fragment of the Yellow River carp defensin protein gene (70-201 bp without the signal peptide), and a flexible linker fusion gene connecting the two gene fragments. Compared with previously reported anti-SVCV vaccines, the oral vaccine against carp spring viremia virus prepared in this invention does not harm the fish during the entire immunization process, is simple to operate, safe and stable, and has a higher protection rate. Therefore, this oral vaccine provides broad prospects for the prevention and control of carp spring viremia.

This invention provides a compound drug for treating melioidosis, its preparation method, and its application. The drug comprises active components of traditional Chinese medicine, a bioactive preparation, and a pharmaceutically acceptable carrier. The active components of traditional Chinese medicine are primarily extracts of Scutellaria baicalensis, Coptis chinensis, Fagopyrum dibotrys, and Polygonum cuspidatum. The bioactive preparation includes polymyxin B, homoserine lactonease, and recombinant human β-defensin 3. The components work synergistically to construct a comprehensive intervention system covering all pathological stages, including biofilm disruption, sterilization, anti-endotoxin activity, intracellular bacterial clearance, immune regulation, and tissue repair. This system can effectively disrupt bacterial biofilms, kill multidrug-resistant strains, neutralize endotoxins, and eliminate latent intracellular bacteria, addressing the core pain points of existing melioidosis treatments, such as strong drug resistance, significant toxic side effects, and high recurrence rates. The preparation process of this invention is carried out under low-temperature and sterile conditions throughout, which fully preserves the stability of the active ingredients, making it suitable for industrial production. The drug can be prepared in various dosage forms, covering all clinical subtypes of melioidosis, and possesses clinical application value and promising prospects for widespread application.

The application discloses a full-gorge hard tick-derived defensin polypeptide and application thereof. The defensin polypeptide is IpDf3, and the amino acid sequence is shown as SEQ ID NO:1. The defensin polypeptide has different degrees of antibacterial activity on four gram-positive bacteria and two gram-negative bacteria. Bactericidal kinetics and scanning electron microscope experiments show that 3*MIC IpDf3 can quickly down-regulate the bacterial number by 1-4 logarithmic units in 60 min, and can cause irregular bulges or depressions on the surface of gram-positive bacteria, and even rupture of the cell membrane, indicating that the antibacterial mechanism may be closely related to the direct damage of the cell membrane. The defensin polypeptide not only has the activity of traditional defensin against gram-positive bacteria, but also has certain antibacterial activity against gram-negative bacteria, has a wide antibacterial spectrum, strong activity, fast bactericidal speed, and is expected to provide a candidate for the research and development of new antibacterial drugs, and has important application prospects.

The application discloses a traditional Chinese medicine exosome compound with anti-HPV and application thereof, and relates to the technical field of biotechnology.The compound comprises functional components secreted by a human cell co-culture system and a traditional Chinese medicine source extract, and the traditional Chinese medicine source extract is derived from a combined traditional Chinese medicine extract of Astragalus membranaceus, Isatis indigotica Fort., Honeysuckle and Sophora flavescens Ait., and relates to the technical field of biotechnology.The traditional Chinese medicine exosome carries natural active ingredients, and a multi-target anti-virus network is formed by beta-defensin-2 and interferon-gamma generated by co-culture with human cells.Compared with single traditional Chinese medicine extract or chemically synthesized nanoparticles, the HPV inhibition rate is increased by more than 170%, and the direct cytotoxicity of traditional Chinese medicine is reduced through an exosome delivery system, and the IC 50 >200ug / mL, which is significantly lower than that of a water decoction, and mucous membrane irritation experiments show no damage.

Provided is a [beta]-defensin-3 mRNA expression promoter comprising dipotassium glycyrrhizinate.

The invention discloses a preparation based on bug defensin as well as a preparation method and application thereof. The prepared porous fiber serves as a carrier, the high-temperature resistance of the bug defensin is improved, the porous fiber and phospholipid-chitosan-sodium alginate form dual protection, the activity of the bug defensin can be effectively guaranteed, the certain high-temperature-resistant activity is achieved, and the excellent feed processing adaptability is achieved. Besides, agricultural waste is adopted to prepare porous fibers, biocompatibility is higher, the porous fibers are loaded and then wrapped, the structure is not prone to being damaged, bad smells of the porous fibers can be covered, the food consumption is increased, immune regulation is participated, growth of animals is effectively promoted, on the whole, the mode of combining loading and wrapping is designed, the process is simple, and the cost is low. The entrapment efficiency is high, the antibacterial and antiviral activity is exerted, meanwhile, drug resistance is not prone to being generated, and the safety performance is high.

The application discloses a preparation method of enteric sustained-release defensin mesoporous silica nanoparticles. The enteric sustained-release defensin mesoporous silica nanoparticles prepared by the method have good defensin loading capacity, good responsiveness to trypsin and good enteric targeting and sustained-release defensin performance.

The application discloses a pig beta-defensin-3 gene core promoter and a construction method and application thereof, and belongs to the technical field of genetic engineering. The sequence of the core promoter is shown as SEQ ID No. 1, the core promoter has significant promoter activity in pig small intestinal epithelial cells, and can be regulated by nutrients such as sodium butyrate and glutamine. The application also discloses a construction method for specifically amplifying the core promoter, which comprises the following steps: performing PCR amplification by taking pig small intestinal epithelial cell DNA as a template, taking the upstream primer and the downstream primer shown as SEQ No. 2-SEQ No. 3 as the primer, constructing a pMD-18T-pBD-3-P recombinant plasmid, and taking the recombinant plasmid as a template to amplify a core promoter fragment. The core promoter provides an excellent experimental system for studying the transcriptional regulation mechanism of the pig beta-defensin-3 gene, the nutrient response characteristics provide a new platform for studying the interaction between nutrition and immunity, and the core promoter has a wide application prospect in the field of healthy breeding of livestock and poultry.

The invention discloses a novel defensin polypeptide sourced from sclerophyllum squarrosum and application of the novel defensin polypeptide. The novel defensin polypeptide is IpDf3, and the amino acid sequence of the novel defensin polypeptide is shown as SEQ ID NO: 1. The compound has different degrees of antibacterial activity to four gram-positive bacteria and two gram-negative bacteria. Bactericidal kinetics and scanning electron microscope experiments show that the IpDf3 of 3 * MIC rapidly down-regulates the colony count by 1-4 logarithmic units within 60 min, and can cause irregular protrusions or recesses on the surfaces of gram-positive bacteria and even rupture of cell membranes, which indicates that the antibacterial mechanism of the IpDf3 is possibly closely related to direct damage of the cell membranes. The defensin polypeptide not only has the anti-gram-positive bacterium activity of traditional defensin, but also has certain antibacterial activity on gram-negative bacteria, is wide in antibacterial spectrum, high in activity and high in sterilization speed, is expected to provide candidates for research and development of novel antibacterial drugs, and has important application prospects.

Provided herein is an antimicrobial composition for hygiene applications. The antimicrobial composition comprises an effective concentration of a cathelicidin LL-37 peptide fragment in combination with an effective concentration of non- ionic surfactant. The non-ionic surfactant is an Alkyl-Poly Glucoside (APG) or alcohol ethoxylates or both. The antimicrobial composition further comprises of a chelating agent like disodium EDTA, or malic acid or citric acid or GLDA or PES A. The composition achieves log reduction of at least 3 against Gram negative bacteria Pseudomonas aeruginosa, Escherichia coll and Gram positive bacteria Staphylococcus aureus, Enterococcus hirae.

The invention discloses an innovative human intestinal alpha defensin 5 (HD5) receptor P2Y11 screening method, platform and application, and belongs to the field of biomedicine.The method fuses multiple omics and experimental strategies, effectively solves the problems that receptor protein is complex and interaction is difficult to independently identify, remarkably improves the accuracy and reliability of defensin receptor identification, and has good application prospects. A set of method system with high universality and wide applicability is provided for receptor research, the first cell receptor P2Y11 of HD5 is successfully identified by the method, and discovery of the P2Y11 receptor not only opens up a new perspective for deep understanding of biological functions and action mechanisms of HD5, but also provides a new potential target for treatment of related diseases; especially for infectious diseases such as bacillary dysentery caused by shigella participated in HD5, a P2Y11 receptor is used as a drug target, possibility is provided for developing a novel treatment scheme, more effective treatment choices are expected to be brought to patients, and the treatment effect and life quality are remarkably improved.

Antimicrobial modified defensins or defensin-like peptides, modified C-terminal fragments of defensins or defensin-like peptides, and nucleic acids encoding the same are disclosed. Also disclosed are compositions comprising the defensin variant peptides and methods of using the same to control microbial infections and feed and food contamination in plant and vertebrate subjects.

Antimicrobial defensin peptide variants comprising modified C-terminal fragments of a defensin and nucleic acids encoding the same are disclosed. Compositions comprising the defensin variant peptides and methods of their use to control microbial infections of plants and vertebrate subjects as well as contamination of feedstuffs and foodstuffs are also disclosed.

This disclosure describes compositions and methods involved in tumor suppression and inhibiting infection of cells by pathogens. Generally, the compositions include an mRNA cargo that can provide a therapeutic benefit after being introduced into an epithelial cell. In some cases, the mRNA can encode a polypeptide. In some cases, the polypeptide can suppress epithelial cell proliferation. In other embodiments, the polypeptide can be involved in innate immunity. In various embodiments, the polypeptide can include cathelicin antimicrobial protein (CAMP), calprotectin, S100A8, S100A9, a β-defensin, S100A7, secretory leukocyte inhibitor, lipocalin 2, or lysozyme. In some embodiments, the mRNA can include a stabilizing moiety such as, for example, a 5′ cap or a 3′ extension.

The present invention relates to methods for maturing the mucosal defense and rebalancing the immune system preventing a cytokine storm; treatment or prevention of neonatal sepsis, necrotizing enterocolitis, acute and prolonged diarrhea, short bowel syndrome, respiratory illness, respiratory infection, respiratory failure, impaired neurodevelopment and extra uterine growth restriction, the method comprising oral and / or intrapulmonary and / or subcutaneous administration of at least one antimicrobial peptide selected from the group consisting of a-defensins, β-defensins, cathelicidins, lactoferrins / lactoferricins and lysozymes and / or GLP-2 or GLP-2 analogs in a preterm infant or a mother about to give birth to a preterm infant.

To develop peptide analogs of a θ-defensin that provide a biphasic effect in treating disseminated fungal disease and / or associated septic shock.SOLUTION: These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address an infective pathogen and then regulating the immune system to down-regulate the inflammatory response. These θ-defensin analogs are protective at concentrations where naturally occurring θ-defensins have no apparent effect, and include a core set of structural and sequence features not found in native θ-defensins.SELECTED DRAWING: Figure 16

A β-defensin-3 mRNA expression promoter containing dipotassium glycyrrhizinate.

The present application provides a black soldier fly defensin C-13326, the nucleotide sequence of the black soldier fly defensin C-13326 is shown as SEQ ID NO.1, and the application of the black soldier fly defensin C-13326 in inhibiting multiple drug-resistant Aeromonas sobria is also provided.The black soldier fly defensin C-13326 provided by the present application can be applied to the preparation of anti-drug-resistant Aeromonas sobria products to cope with the serious harm caused by drug-resistant Aeromonas sobria.